Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options on June 25, 2025 Biotech Layoffs Clinical Trials FL-501 Flatulence LEAP Sirexatamab strategic alternatives +
Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions on April 29, 2025 Autoimmune Diseases B cell immunomodulator program biology (field) Flatulence Nordisk alliance OCT50 Programs - Publication Format +